FDA
-
-
-
-
-
-
-
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
-
-
-
-
-
-
-
Valneva Hosts Investor Day in New York City
-
-
-
-
-
-
-
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
-
-
-
-
-
-
-
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine
-
-
-
-
-
-
-
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
-
-
-
-
-
-
-
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
-
-
-
-
-
-
-
Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine Candidate
-
322,246 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

